RxDoctor Payments DataLook up a doctor →

Champalal Gupta, MD

Internal Medicine · Milwaukee, WINPI 1962418236

Payments from drug & device makers

$9,451in general payments, 2019–2025

Across 546 payments — averaging $17.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • AstraZeneca$887
  • AbbVie$837
  • Otsuka America Pharmaceutical, Inc.$502
  • Neurocrine Biosciences, Inc.$483
  • Pfizer$455
  • plus $4K from 51 others

What the payments were for

  • Food & beverage$9,438100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,451 in reported general payments places this provider in the 95th percentile of 1,411 internal medicine providers in Wisconsin.

See all internal medicine providers in Wisconsin

Medicare billing

Part B allowed, 2024
$28,130
Medicare patients
45
Services billed
311

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban181$95,317
LinzessLinaclotide108$75,662
JanuviaSitagliptin Phosphate72$48,107
TradjentaLinagliptin43$29,342
JardianceEmpagliflozin32$25,891
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$24,820
SymbicortBudesonide/Formoterol Fumarate81$22,312
Spiriva HandihalerTiotropium Bromide41$21,809
Combivent RespimatIpratropium/Albuterol Sulfate31$15,128
Breztri AerosphereBudesonide/Glycopyr/Formoterol19$13,664
EntrestoSacubitril/Valsartan17$10,849
JanumetSitagliptin Phos/Metformin Hcl23$7,562
Breo ElliptaFluticasone/Vilanterol16$6,145
Albuterol Sulfate HfaAlbuterol Sulfate244$5,517
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate26$4,989

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$455$95,317181 claims
AbbVieLinzess$837$75,662108 claims
Boehringer IngelheimTradjenta, Jardiance, Combivent Respimat$265$70,361106 claims
MerckJanuvia, Janumet$25$55,66995 claims
AstraZenecaSymbicort, Breztri Aerosphere$887$35,976100 claims
GSKTrelegy Ellipta, Breo Ellipta$112$30,96553 claims
NovartisEntresto$357$10,84917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,411 internal medicine providers in Wisconsin.

Other internal medicine in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →